Last reviewed · How we verify

intravenous application of tranexamic acid

Chang Gung Memorial Hospital · FDA-approved active Small molecule Quality 2/100

intravenous application of tranexamic acid is a Small molecule drug developed by Chang Gung Memorial Hospital. It is currently FDA-approved. Also known as: transamine.

Intravenous tranexamic acid, marketed by Chang Gung Memorial Hospital, holds a position in the antifibrinolytic market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and clinical efficacy, which supports its current market presence. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameintravenous application of tranexamic acid
Also known astransamine
SponsorChang Gung Memorial Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intravenous application of tranexamic acid

What is intravenous application of tranexamic acid?

intravenous application of tranexamic acid is a Small molecule drug developed by Chang Gung Memorial Hospital.

Who makes intravenous application of tranexamic acid?

intravenous application of tranexamic acid is developed and marketed by Chang Gung Memorial Hospital (see full Chang Gung Memorial Hospital pipeline at /company/chang-gung-memorial-hospital).

Is intravenous application of tranexamic acid also known as anything else?

intravenous application of tranexamic acid is also known as transamine.

What development phase is intravenous application of tranexamic acid in?

intravenous application of tranexamic acid is FDA-approved (marketed).

Related